Medifron DBT Co., Ltd. announced that it has entered into a private placement to issue 8,666,661 convertible preferred shares at a price of KRW 1,500 per share for gross proceeds of KRW 12,999,991,500 on June 22, 2022. The transaction will include participation from new investors SFS International Co., Ltd. for 333,333 shares, Hanyang Securities Co., Ltd. for 333,333 shares, Best Investment & Securities Co., Ltd. for 666,666 shares, Synergy 4th Industry No. 16 New Technology Business Fund, JW KOSDAQ Venture IPO General Private Equity Trust No.

1, KY KOSDAQ Venture Specialized Investment Criminal Equity Trust No. 3, funds managed by KB Securities Co., Ltd. for 1,333,333 shares, ASEM KOSDAQ Venture Plus General Private Equity Trust No.8, funds managed by Korea Investment & Securities Co., Ltd. for 666,666 shares, Tiger KOSDAQ Venture With Mezzanine 317 General Private Equity Trust, Tiger KOSDAQ Venture Mezzanine Driven 318 General Private Equity Trust, Tiger KOSDAQ Venture Beyond Mezzanine 319 General Private Equity Trust, Pita KOSDAQ Venture General Private Equity Trust No.2, EIP ESG No. 1 General Private Equity Trust for KOSDAQ Venture, funds managed by NH Investment & Securities Co., Ltd for 999,999 shares.

and individual investors Sang-soo Kim for 666,666 shares, Shin Kyun Lee for 666,666 shares, Jonghoon Lee for 1,333,333 shares and Bok-gi Kim for 333,333 shares. The preferred shares will be convertible into 8,666,661 common shares of the company at a conversion price of KRW 1,500 per share. The conversion period will start from July 1, 2023 to June 30, 2027.

The securities issued in the transaction will be subject to a hold period of 1 year from the date of issuance. The transaction has been approved by the board of directors of the company. The expected payment date of the transaction is June 30, 2022.